harmaceutical manufacturing improvements that could benefit patients quickly often take months to implement. For example, a packaging update designed to reduce medication errors may sit idle across multiple markets because regulators require an updated Certificate of Pharmaceutical Product (CPP), typically issued by a reference authority such as the European Medicines Agency (EMA) or US Food & Drug Administration (FDA), before a post-approval change (PAC) submission can be filed in their own jurisdiction. Until the CPP is reissued, review timelines cannot begin.

PACs are essential to keeping medicines current, but they remain among the most complex areas of global regulatory practice. Differing classifications, inconsistent documentation expectations, mixed legacy processes, and uneven digital maturity slow implementation. A facility may be upgraded in one region while products elsewhere still rely on older equipment or inefficient processes simply because regulatory approvals cannot be synchronized, leading to avoidable supply constraints.

This article highlights key friction points and emerging solutions across major global regions.

What Slows PAC Implementation?

1. Varying regulatory expectations create operational bottlenecks
PACs sit at the intersection of several regulatory layers:

• International standards (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Q8-Q12)
• Regional frameworks including the EMA Variation Regulation Guidelines
• National requirements

Even when countries reference similar guidelines, execution frequently differs.

Example: A manufacturing process update classified as a Type II variation (a major change with significant impact on product quality, safety, or efficacy) in the European Union (EU) with a structured 60-day review may require:

• A full dossier and local testing in Brazil.
• A supplementary efficacy assessment in parts of Asia where The Association of Southeast Asian Nations (ASEAN) Pharmaceutical Framework positions efficacy as part of quality-related changes.
• A new CPP following reference authority approval in several ASEAN and Middle East & North Africa (MENA) markets. (See previous Global Forum Special Sections on CPP in September and October 2024.)

Impact: A company introducing packaging line optimization across more than 40 markets encountered eight-month delays in Wave 2 markets (Brazil, China, and Saudi Arabia) because submissions could not begin until updated EU approval and CPP were available. Wave 2 markets typically follow initial approvals in reference markets such as the EU or US.

2. Conflicting stability expectations add avoidable delays
The EMA and the FDA accept concurrent stability studies for certain low-risk PACs. Several ASEAN national regulatory authorities (NRAs) along with the Egyptian Drug Authority require three full batches of completed stability data at submission even when the change is low risk.

Impact: Stability neutral excipient updates have taken more than 12 months in some markets, despite robust evidence demonstrating no quality or safety concerns.

Cross-functional implications: Manufacturing must adjust production schedules, supply chain groups increase safety stock, quality may release product under dual conditions, and affiliates face forecasting uncertainty, thereby creating ripple effects across the product lifecycle.

3. Regional nuance and regional digital readiness: two distinct challenges
These dimensions often get conflated but require separate management.

Classification → Digital constraint: Risk-based PAC classifications only deliver benefit when digital systems support modular or incremental updates. Without this, low-risk changes are processed like major variations.

Digital → Regulatory constraint: Advanced eCTD platforms cannot accelerate PACs if regional rules still require CPPs, local studies, or conservative reclassification.

A country may have modern, risk-based PAC categories but lack the digital infrastructure to process submissions efficiently—or the reverse.

Where Differences Matter Most

Europe: Progress but uneven execution
Recent EU pharmaceutical legislation reform, the most comprehensive in decades, aims to simplify variations, leverage real-world evidence through the Data Analysis and Real-World Interrogation Network (DARWIN EU), and advance digital modernizations including eCTD 4.0 and Electronic Product Information (ePI) pilots. However:

• Member states differ in documentation depth, national portal requirements, and implementation timelines, meaning the same PAC may be accepted with high-level justification in one country but trigger additional evidence requests in another.
• Digital capacity varies; for example, the Netherlands and Denmark lead eCTD 4.0 adoption, while others are still preparing.
• Biological PACs reveal the widest gaps: One authority may accept a process characterization summary, while another requests full development reports. Both approaches are scientifically valid, but differences create delays and duplicated work.

Underlying issue: Harmonized policy but heterogenous execution.

Emerging markets: Rapid innovation but uneven adoption of innovation
Many emerging agencies are moving quickly toward digitalization and risk-based PAC models.

Collectively, these efforts signal convergence, though digital readiness remains variable.

Digital Readiness: The Quiet Determinant of PAC Success

Digitalization is reshaping PAC execution, but benefits depend on process integration rather than tool adoption alone.

Artificial intelligence (AI)-assisted authoring
Teams are increasingly validating generative AI tools to streamline Module 3 updates by structuring content to ICH and EMA standards, reusing approved content with full traceability, and pre-populating routine PAC sections.

Example: In an AI pilot with a leading regulatory technology platform, Module 3 content significantly reduced drafting time, improved consistency, and enabled faster turnaround and more standardized formatting.

Natural Language Processing (NLP) anticipates regulator questions
NLP models analyzing historical health authority queries help identify recurring themes, such as:

• Comparability justifications
• Batch analysis queries
• Stability strategy clarifications
• Validation questions.

Example: Across EU and Gulf Cooperation Council (GCC) markets, PAC queries have often focused on comparability protocols. The European Federation of Pharmaceutical Industries and Associations (EFPIA) reference document on PAC management protocols highlights that updated risk assessments and clear pre-submission clarifications can reduce regulatory follow-up questions.

Regulatory intelligence enhances planning
EMA’s Integrated Regulatory Information System (IRIS), FDA’s Knowledge-Aided Assessment & Structured Application (KASA), and the World Health Organization (WHO) Collaborative Registration Procedure provide near-real-time regulatory updates that help companies:

• Detect new validation or stability expectations
• Monitor portal readiness
• Adjust submission timing based on evolving regulatory signals.

Example: A sterilization PAC across 24 markets avoided rejection after early detection of updated stability requirements in two ASEAN regions, as outlined in the ASEAN Guideline on Stability Study of Drug Product. This proactive adjustment enabled timely dossier adjustments.

Collaboration Over Competition: The Path Forward

Extending reliance models to PACs
Existing collaborative frameworks already demonstrate successful shared assessment:

• Project Orbis: FDA-led framework enabling concurrent international review of oncology drugs to accelerate access.
• ACCESS Consortium: Regulatory partnership (Australia, Canada, Singapore, Switzerland, and United Kingdom) that aligns requirements and shares scientific reviews.
• WHO Collaborative Registration Procedure (CRP): Reliance pathway allowing national authorities to use WHO or stringent regulatory assessments for faster approvals.
• International Coalition of Medicines Regulatory Authorities (ICMRA): Global coalition supporting joint evaluation of dossier components such as quality modules, Good Manufacturing Practice (GMP) information, or PAC-related changes.

Because PACs rely on established data, they are ideal candidates for incorporation into the regulatory reliance framework.

Cocreated digital governance
Regulators and industry are already collaborating:

• The EMA-Heads of Medicines Agencies (HMA) Big Data Steering Group has set out principles for validating AI in regulatory use.
• Health Canada’s “AI in Health” regulatory sandbox is codeveloping AI assurance frameworks with industry.
• Singapore’s Health Sciences Authority (HSA) is piloting digital structured eCTD quality module submissions.

Scaling these initiatives will require:

• AI validation standards ensuring transparency, traceability, and interpretability of algorithms
• Common data models with structured fields and clear metadata
• Secure cross-border data systems aligned with privacy and cybersecurity rules.

Broader Implications: Patients Feel the Most Impact

Patients seldom hear the term “post-approval changes,” yet they directly determine whether medicines are:

• Produced to the latest quality standards
• Packaged in the safest formats
• Supported by resilient global supply chains.

In regions where PAC approvals can take many months, especially for biologics in parts of ASEAN markets, patients may experience product shortages or continue receiving medicines manufactured under outdated processes.

Predictability in PAC pathways is more than just an operational efficiency metric; it is a fundamental enabler of patient access.

Regulatory Ambition Meets Operational Reality

PAC implementation is where regulatory ambition meets operational reality. To close the gaps, three actions should anchor the global agenda:

1. Develop shared frameworks for AI validation and data integrity to build trust in digital tools and analytics.
2. Extend reliance and collaborative models to include PACs, leveraging proven mechanisms to enable faster, more consistent global implementation of PACs.
3. Invest in digital capacity building to help all markets participate in modern regulatory pathways.

Ultimately, the goal remains simple: To ensure that every patient in every region receives timely access to safe, high-quality therapies manufactured according to the most current standards.